Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04255433 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 13,299
- Enrollment target
NCT04255433 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 13,299 participants.
The verdict
NCT04255433, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13,299 participants
- Enrollment target
Study Summary
The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
Interventions
- DRUG Tirzepatide
- DRUG Dulaglutide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,299 participants |
| Start Date | 2020-05-29 |
| Est. Completion | 2025-06-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04255433
The ClinicalTrials.gov registry entry for NCT04255433 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 13,299 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tirzepatide is the first listed.
NCT04255433 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04255433 about?
NCT04255433 is a clinical study titled "A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes". The purpose of the trial is to assess the efficacy and safety of tirzepatide to dulaglutide in participants with type 2 diabetes and increased cardiovascular risk.
What is the current status of trial NCT04255433?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13,299 participants. The study started on 2020-05-29. Estimated completion is 2025-06-12.
What interventions are being tested in trial NCT04255433?
The interventions under investigation include: Tirzepatide (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT04255433?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.